Seven scientists will be awarded $600,000 in grants dedicated to osteosarcoma research from MIB Agents, a pediatric osteosarcoma nonprofit. The scientists will be presented their grants at the MIB Agents’ FACTOR Conference in Atlanta, Georgia, this June.
Addition of the immunotherapy drug pembrolizumab (Keytruda) to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial led by researchers from the University of Pittsburgh, UPMC, Duke University, and Princess Margaret Cancer Centre.
